260 related articles for article (PubMed ID: 7660855)
21. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
Lissoni P; Pittalis S; Rovelli F; Vigorè L; Roselli MG; Brivio F
J Biol Regul Homeost Agents; 1995; 9(2):63-6. PubMed ID: 9127635
[TBL] [Abstract][Full Text] [Related]
22. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
23. Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer.
Muc-Wierzgon M; Nowakowska-Zajdel E; Zubelewicz B; Wierzgon J; Kokot T; Klakla K; Szkilnik R; Wiczkowski A
J Exp Clin Cancer Res; 2003 Jun; 22(2):171-8. PubMed ID: 12866566
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
25. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
Lissoni P; Ardizzoia A; Tisi E; Rossini F; Barni S; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1993; 7(1):34-6. PubMed ID: 8346714
[TBL] [Abstract][Full Text] [Related]
26. Anti-angiogenic activity of melatonin in advanced cancer patients.
Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha.
Lissoni P; Ardizzoia A; Perego MS; Grassi MG; Arosio M; D'Amico P; Cazzaniga M; Crispino S; Tancini G; Barni S
J Biol Regul Homeost Agents; 1993; 7(2):73-5. PubMed ID: 8266818
[TBL] [Abstract][Full Text] [Related]
28. The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia.
Lissoni P; Tancini G; Barni S; Paolorossi F; Rossini F; Maffé P; Di Bella L
Recenti Prog Med; 1996 Dec; 87(12):582-5. PubMed ID: 9066251
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease.
Ardizzoia A; Lissoni P; Brivio F; Tisi E; Perego MS; Grassi MG; Pittalis S; Crispino S; Barni S; Tancini G
J Biol Regul Homeost Agents; 1992; 6(3):103-7. PubMed ID: 1492596
[TBL] [Abstract][Full Text] [Related]
30. Pineal-opioid system interactions in the control of immunoinflammatory responses.
Lissoni P; Barni S; Tancini G; Fossati V; Frigerio F
Ann N Y Acad Sci; 1994 Nov; 741():191-6. PubMed ID: 7825805
[TBL] [Abstract][Full Text] [Related]
31. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
J Biol Regul Homeost Agents; 1993; 7(4):121-5. PubMed ID: 8023699
[TBL] [Abstract][Full Text] [Related]
32. Effect of TNF-alpha on the melatonin synthetic pathway in the rat pineal gland: basis for a 'feedback' of the immune response on circadian timing.
Fernandes PA; Cecon E; Markus RP; Ferreira ZS
J Pineal Res; 2006 Nov; 41(4):344-50. PubMed ID: 17014691
[TBL] [Abstract][Full Text] [Related]
33. Role of circadian rhythm and endogenous melatonin in pathogenesis of acute gastric bleeding erosions induced by stress.
Brzozowski T; Zwirska-Korczala K; Konturek PC; Konturek SJ; Sliwowski Z; Pawlik M; Kwiecien S; Drozdowicz D; Mazurkiewicz-Janik M; Bielanski W; Pawlik WW
J Physiol Pharmacol; 2007 Dec; 58 Suppl 6():53-64. PubMed ID: 18212400
[TBL] [Abstract][Full Text] [Related]
34. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
[TBL] [Abstract][Full Text] [Related]
35. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni GJ
Anticancer Res; 1990; 10(6):1759-61. PubMed ID: 2285255
[TBL] [Abstract][Full Text] [Related]
36. [The studies of melatonin values in the cerebrospinal fluid of hydrocephalic patients].
Kurisaka M; Miyake H; Eghwrudjakpor PO; Mori K
No To Shinkei; 1991 Jul; 43(7):631-6. PubMed ID: 1910947
[TBL] [Abstract][Full Text] [Related]
37. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
Lissoni P; Barni S; Tancini G; Rovelli F; Ardizzoia A; Conti A; Maestroni GJ
Oncology; 1993; 50(6):399-402. PubMed ID: 8233281
[TBL] [Abstract][Full Text] [Related]
38. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppresses nocturnal melatonin production.
Pontes GN; Cardoso EC; Carneiro-Sampaio MM; Markus RP
J Pineal Res; 2007 Nov; 43(4):365-71. PubMed ID: 17910605
[TBL] [Abstract][Full Text] [Related]
39. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
Lissoni P; Rovelli F; Brivio F; Fumagalli L; Brera G
In Vivo; 2008; 22(3):397-400. PubMed ID: 18610754
[TBL] [Abstract][Full Text] [Related]
40. Human pineal physiology and functional significance of melatonin.
Macchi MM; Bruce JN
Front Neuroendocrinol; 2004; 25(3-4):177-95. PubMed ID: 15589268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
